W. Schunack

发表

Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug.

P. Lavie, J. Schwartz, H. Stark, 1997, The Journal of pharmacology and experimental therapeutics.

The histamine H3 receptor and its ligands.

J. Schwartz, H. Stark, J. Arrang, 2001, Progress in medicinal chemistry.

Highly potent and selective ligands for histamine H3-receptors

J. Schwartz, J. Arrang, J. Lecomte, 1987, Nature.

BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology

L Landais, C R Ganellin, J. Schwartz, 2007, Journal of Pharmacology and Experimental Therapeutics.

Novel histamine H3 receptor antagonists: affinities in an H3 receptor binding assay and potencies in two functional H3 receptor models

H. Stark, W. Schunack, M. Kathmann, 1994, British journal of pharmacology.

Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay.

U. Jaehde, C. Kloft, W. Schunack, 1999, Therapeutic drug monitoring.

Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine.

A. Buschauer, B. Czarnetzki, G. Frank, 1994, The Journal of allergy and clinical immunology.

Performance monitoring by the supplementary eye ® eld

J. Schall, V. Stuphorn, T. L. Taylor, 2000 .

Monitoring of chemotherapy-induced proteinuria using capillary zone electrophoresis.

U. Jaehde, W. Schunack, J. Gysler, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain

C R Ganellin, J. Schwartz, H. Stark, 2000, British journal of pharmacology.

[125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors.

J. Schwartz, H. Stark, J. Díaz, 1994, The Journal of pharmacology and experimental therapeutics.

Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.

J. Schwartz, H. Stark, C. Ganellin, 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists.

J. Schwartz, H. Stark, J. Arrang, 2000, Bioorganic & medicinal chemistry letters.

Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity.

J. Schwartz, H. Stark, J. Arrang, 1996, Journal of medicinal chemistry.

Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H2 receptor using [125I]iodinated probes.

M. Bouthenet, J. Schwartz, A. Buschauer, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.

M. Garbarg, W. Schunack, S. Elz, 1995, Journal of medicinal chemistry.

Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H(3)-receptor agonist prodrug.

J. Schwartz, H. Stark, A. Rouleau, 2000, The Journal of pharmacology and experimental therapeutics.

Histamine H3 receptor binding sites in rat brain membranes: modulations by guanine nucleotides and divalent cations.

J. Schwartz, J. Arrang, W. Schunack, 1990, European journal of pharmacology.

Effects of iodoproxyfan, a potent and selective histamine H3 receptor antagonist, onα2 and 5-HT3 receptors

H. Pertz, K. Purand, W. Schunack, 1995, Inflammation Research.

Evidence for hypernociception induction following histamine H1 receptor activation in rodents.

W. Schunack, A. Bartolini, P. Malmberg-Aiello, 1998, Life sciences.